Epigenetics of lung cancer

Translational Research

Volumn 165, Issue 1, 2015, Pages 74-90

  Langevin, Scott M ^a   Kratzke, Robert A ^b   Kelsey, Karl T ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CARCINOGENESIS; DNA METHYLATION; EPIGENETICS; HUMAN; LUNG CANCER; META ANALYSIS (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TISSUE SPECIFICITY; TUMOR SUPPRESSOR GENE; ANIMAL; CLINICAL TRIAL (TOPIC); FEMALE; GENETIC EPIGENESIS; GENETICS; LUNG NEOPLASMS; MALE; METABOLISM; PROGNOSIS; RISK FACTOR; TRANSLATIONAL RESEARCH;

ANIMALS; BIOMARKERS, TUMOR; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; PROGNOSIS; RISK FACTORS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84919847817     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2014.03.001     Document Type: Review

References (279)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. C.S. Dela Cruz, L.T. Tanoue, and R.A. Matthay Lung cancer: epidemiology, etiology, and prevention Clin Chest Med 32 2011 605 644
3. F. Lu, and H.T. Zhang DNA methylation and nonsmall cell lung cancer Anat Rec 294 2011 1787 1795
4. P.P. Massion, and D.P. Carbone The molecular basis of lung cancer: molecular abnormalities and therapeutic implications Respir Res 4 2003 12
5. S.A. Selamat, J.S. Galler, and A.D. Joshi DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma PLoS One 6 2011 e21443
6. Z. Herceg, and T. Vaissiere Epigenetic mechanisms and cancer: an interface between the environment and the genome Epigenetics 6 2011 804 819
7. S.M. Langevin, and K.T. Kelsey The fate is not always written in the genes: epigenomics in epidemiologic studies Environ Mol Mutagenesis 54 2013 533 541
8. R.G. Dumitrescu Epigenetic markers of early tumor development Methods Mol Biol 863 2012 3 14
9. E. Brzezianska, A. Dutkowska, and A. Antczak The significance of epigenetic alterations in lung carcinogenesis Mol Biol Rep 40 2013 309 325
10. S.A. Belinsky, D.M. Klinge, and J.D. Dekker Gene promoter methylation in plasma and sputum increases with lung cancer risk Clin Cancer Res 11 2005 6505 6511
11. S. Zochbauer-Muller, J.D. Minna, and A.F. Gazdar Aberrant DNA methylation in lung cancer: biological and clinical implications Oncologist 7 2002 451 457
12. J.H. Chung, H.J. Lee, B.H. Kim, N.Y. Cho, and G.H. Kang DNA methylation profile during multistage progression of pulmonary adenocarcinomas Virchow Arch 459 2011 201 211
13. J.D. Licchesi, W.H. Westra, C.M. Hooker, and J.G. Herman Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung Clin Cancer Res 14 2008 2570 2578
14. A.H. Berger, A.G. Knudson, and P.P. Pandolfi A continuum model for tumour suppression Nature 476 2011 163 169
15. S. Toyooka, T. Mitsudomi, and J. Soh Molecular oncology of lung cancer Gen Thorac Cardiovasc Surg 59 2011 527 537
16. J.R. Fischer, U. Ohnmacht, and N. Rieger Prognostic significance of RASSF1A promoter methylation on survival of non-small cell patients with lung cancer treated with gemcitabine Lung Cancer 56 2007 115 123
17. O. Topaloglu, M.O. Hoque, and Y. Tokumaru Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer Clin Cancer Res 10 2004 2284 2288
18. S.A. Belinsky, K.J. Nikula, and W.A. Palmisano Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis Proc Natl Acad Sci U S A 95 1998 11891 11896
19. G.J. Nuovo, T.W. Plaia, S.A. Belinsky, S.B. Baylin, and J.G. Herman In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis Proc Natl Acad Sci U S A 96 1999 12754 12759
20. W.A. Palmisano, K.K. Divine, and G. Saccomanno Predicting lung cancer by detecting aberrant promoter methylation in sputum Cancer Res 60 2000 5954 5958
21. D.H. Kim, H.H. Nelson, and J.K. Wiencke p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer Cancer Res 61 2001 3419 3424
22. L. Buckingham, L. Penfield Faber, and A. Kim PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell patients with lung cancer Int J Cancer 126 2010 1630 1639
23. S. Nakata, K. Sugio, and H. Uramoto The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance Cancer 106 2006 2190 2199
24. W. Sterlacci, A. Tzankov, and L. Veits A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas J Thorac Oncol 6 2011 1649 1657
25. J.A. Tsou, J.S. Galler, and K.D. Siegmund Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma Mol Cancer 6 2007 70
26. M. Gasco, A.K. Bell, and V. Heath Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity Cancer Res 62 2002 2072 2076
27. D.S. Kim, S.I. Cha, and J.H. Lee Aberrant DNA methylation profiles of non-small cell lung cancers in a Korean population Lung Cancer 58 2007 1 6
28. N. Shivapurkar, V. Stastny, and M. Suzuki Application of a methylation gene panel by quantitative PCR for lung cancers Cancer Lett 247 2007 56 71
29. X. Tang, F.R. Khuri, and J.J. Lee Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer J Natl Cancer Inst 92 2000 1511 1516
30. R. Dammann, M. Strunnikova, and U. Schagdarsurengin CpG island methylation and expression of tumour-associated genes in lung carcinoma Eur J Cancer 41 2005 1223 1236
31. H.H. Nelson, C.J. Marsit, and B.C. Christensen Key epigenetic changes associated with lung cancer development: results from dense methylation array profiling Epigenetics 7 2012 559 566
32. C. Chen, N. Yin, B. Yin, and Q. Lu DNA methylation in thoracic neoplasms Cancer Lett 301 2011 7 16
33. G. Heller, C.C. Zielinski, and S. Zochbauer-Muller Lung cancer: from single-gene methylation to methylome profiling Cancer Metastasis Rev 29 2010 95 107
34. W. Li, J. Deng, P. Jiang, and J. Tang Association of 5′-CpG island hypermethylation of the FHIT gene with lung cancer in southern-central Chinese population Cancer Biol Ther 10 2010 997 1000
35. C. Verri, L. Roz, and D. Conte Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project Am J Respir Crit Care Med 179 2009 396 401
36. N. Yanagawa, G. Tamura, and H. Oizumi Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers Lung Cancer 58 2007 131 138
37. Y. Tomizawa, H. Iijima, and T. Nomoto Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer Lung Cancer 46 2004 305 312
38. S. Begum, M. Brait, and S. Dasgupta An epigenetic marker panel for detection of lung cancer using cell-free serum DNA Clin Cancer Res 17 2011 4494 4503
39. H.J. Grote, V. Schmiemann, and S. Kiel Aberrant methylation of the adenomatous polyposis coli promoter 1A in bronchial aspirates from patients with suspected lung cancer Int J Cancer 110 2004 751 755
40. S. Toyooka, R. Maruyama, and K.O. Toyooka Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer Int J Cancer 103 2003 153 160
41. J. Brabender, H. Usadel, and K.D. Danenberg Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival Oncogene 20 2001 3528 3532
42. M. Ji, H. Guan, C. Gao, B. Shi, and P. Hou Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC) BMC Cancer 11 2011 147
43. S.M. Lee, W.K. Lee, D.S. Kim, and J.Y. Park Quantitative promoter hypermethylation analysis of RASSF1A in lung cancer: comparison with methylation-specific PCR technique and clinical significance Mol Med Rep 5 2012 239 244
44. W. Niklinska, W. Naumnik, A. Sulewska, M. Kozlowski, W. Pankiewicz, and R. Milewski Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC) Folia Histochem Cytobiol 47 2009 275 280
45. R. Dammann, T. Takahashi, and G.P. Pfeifer The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas Oncogene 20 2001 3563 3567
46. D.H. Kim, H.H. Nelson, and J.K. Wiencke Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer Oncogene 20 2001 1765 1770
47. A.K. Virmani, A. Rathi, and S. Zochbauer-Muller Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas J Natl Cancer Inst 92 2000 1303 1307
48. M. Ekim, V. Caner, N. Buyukpinarbasili, E. Tepeli, L. Elmas, and G. Bagci Determination of O(6)-methylguanine DNA methyltransferase promoter methylation in non-small cell lung cancer Genet Test Mol Biomarkers 15 2011 357 360
49. J.C. Lai, Y.W. Cheng, and Y.G. Goan Promoter methylation of O(6)-methylguanine-DNA-methyltransferase in lung cancer is regulated by p53 DNA Repair 7 2008 1352 1363
50. J. Brabender, H. Usadel, and R. Metzger Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome Clin Cancer Res 9 2003 223 227
51. B. Schmidt, V. Liebenberg, and D. Dietrich SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates BMC Cancer 10 2010 600
52. K.U. Schneider, D. Dietrich, and M. Fleischhacker Correlation of SHOX2 gene amplification and DNA methylation in lung cancer tumors BMC Cancer 11 2011 102
53. G.P. Yu, Y. Ji, and G.Q. Chen Application of RUNX3 gene promoter methylation in the diagnosis of non-small cell lung cancer Oncol Lett 3 2012 159 162
54. M.F. Omar, K. Ito, and M.E. Nga RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status Pathol Oncol Res 18 2012 783 792
55. K. Sato, Y. Tomizawa, and H. Iijima Epigenetic inactivation of the RUNX3 gene in lung cancer Oncol Rep 15 2006 129 135
56. T.Y. Kim, H.J. Lee, and K.S. Hwang Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma Lab Invest 84 2004 479 484
57. Q.L. Li, H.R. Kim, and W.J. Kim Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer Biochem Biophys Res Commun 314 2004 223 228
58. D.S. Kim, M.J. Kim, J.Y. Lee, Y.Z. Kim, E.J. Kim, and J.Y. Park Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features Cancer 110 2007 2785 2792
59. G. Heller, K.M. Fong, and L. Girard Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas Oncogene 25 2006 959 968
60. S. Kikuchi, D. Yamada, and T. Fukami Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma Cancer 106 2006 1751 1758
61. T. Fukami, H. Fukuhara, and M. Kuramochi Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines Int J Cancer 107 2003 53 59
62. J.L. Ramirez, C. Sarries, and P.L. de Castro Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell patients with lung cancer Cancer Lett 193 2003 207 216
63. A. Virmani, A. Rathi, and K. Sugio Aberrant methylation of TMS1 in small cell, non small cell lung cancer and breast cancer Int J Cancer 106 2003 198 204
64. S. Kikuchi, D. Yamada, and T. Fukami Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer Clin Cancer Res 11 2005 2954 2961
65. C.J. Marsit, S. Zheng, and K. Aldape PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration Hum Pathol 36 2005 768 776
66. J.C. Soria, H.Y. Lee, and J.I. Lee Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation Clin Cancer Res 8 2002 1178 1184
67. P.P. Grimminger, M.K. Maus, and P.M. Schneider Glutathione S-transferase PI (GST-PI) mRNA expression and DNA methylation is involved in the pathogenesis and prognosis of NSCLC Lung Cancer 78 2012 87 91
68. D. Vallbohmer, J. Brabender, and D. Yang DNA methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value Clin Lung Cancer 8 2006 39 44
69. S.A. Belinsky Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer Carcinogenesis 26 2005 1481 1487
70. Q. Lin, J. Geng, and K. Ma RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China J Cancer Res Clin Oncol 135 2009 1675 1684
71. T. Rauch, Z. Wang, and X. Zhang Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay Proc Natl Acad Sci U S A 104 2007 5527 5532
72. M. Yano, S. Toyooka, and K. Tsukuda Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers Int J Cancer 113 2005 59 66
73. H. Chen, M. Suzuki, and Y. Nakamura Aberrant methylation of FBN2 in human non-small cell lung cancer Lung Cancer 50 2005 43 49
74. Z. Liu, W. Li, and Z. Lei CpG island methylator phenotype involving chromosome 3p confers an increased risk of non-small cell lung cancer J Thorac Oncol 5 2010 790 797
75. Z. Liu, J. Zhao, and X.F. Chen CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer Lung Cancer 62 2008 15 22
76. C.J. Marsit, E.A. Houseman, and B.C. Christensen Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors Cancer Res 66 2006 10621 10629
77. K. Shinjo, Y. Okamoto, and B. An Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma Carcinogenesis 33 2012 1277 1285
78. H. Kim, Y.M. Kwon, and J.S. Kim Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer Cancer 107 2006 1042 1049
79. R.K. Lin, H.S. Hsu, J.W. Chang, C.Y. Chen, J.T. Chen, and Y.C. Wang Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer Lung Cancer 55 2007 205 213
80. A. Anisowicz, H. Huang, and K.I. Braunschweiger A high-throughput and sensitive method to measure global DNA methylation: application in lung cancer BMC Cancer 8 2008 222
81. A. Daskalos, S. Logotheti, and S. Markopoulou Global DNA hypomethylation-induced deltaNp73 transcriptional activation in non-small cell lung cancer Cancer Lett 300 2011 79 86
82. A.P. Feinberg, and B. Vogelstein Hypomethylation of ras oncogenes in primary human cancers Biochem Biophys Res Commun 111 1983 47 54
83. A.P. Feinberg, and B. Vogelstein Hypomethylation distinguishes genes of some human cancers from their normal counterparts Nature 301 1983 89 92
84. M. Kondo, H. Suzuki, and R. Ueda Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers Oncogene 10 1995 1193 1198
85. T.A. Rauch, X. Zhong, and X. Wu High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer Proc Natl Acad Sci U S A 105 2008 252 257
86. C.A. Glazer, I.M. Smith, and M.F. Ochs Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC PLoS One 4 2009 e8189
87. S.H. Kim, S. Lee, and C.H. Lee Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration Lung 187 2009 401 411
88. G. Kayser, W. Sienel, and B. Kubitz Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression Pathology 43 2011 719 724
89. S. Renaud, E.M. Pugacheva, and M.D. Delgado Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors Nucl Acid Res 35 2007 7372 7388
90. J.A. Hong, Y. Kang, and Z. Abdullaev Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells Cancer Res 65 2005 7763 7774
91. V.M. Radhakrishnan, T.J. Jensen, H. Cui, B.W. Futscher, and J.D. Martinez Hypomethylation of the 14-3-3sigma promoter leads to increased expression in non-small cell lung cancer Genes Chromosom Cancer 50 2011 830 836
92. A. Shiba-Ishii, and M. Noguchi Aberrant stratifin overexpression is regulated by tumor-associated CpG demethylation in lung adenocarcinoma Am J Pathol 180 2012 1653 1662
93. Y. Gu, C. Wang, Y. Wang, X. Qiu, and E. Wang Expression of thymosin beta10 and its role in non-small cell lung cancer Hum Pathol 40 2009 117 124
94. S.J. Jang, J.C. Soria, and L. Wang Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis Cancer Res 61 2001 7959 7963
95. K. Gronbaek, C. Hother, and P.A. Jones Epigenetic changes in cancer APMIS 115 2007 1039 1059
96. W.M. Rideout 3rd, G.A. Coetzee, A.F. Olumi, and P.A. Jones 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes Science 249 1990 1288 1290
97. J.X. Chen, Y. Zheng, M. West, and M.S. Tang Carcinogens preferentially bind at methylated CpG in the p53 mutational hot spots Cancer Res 58 1998 2070 2075
98. M.F. Denissenko, A. Pao, M. Tang, and G.P. Pfeifer Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53 Science 274 1996 430 432
99. J.H. Yoon, L.E. Smith, Z. Feng, M. Tang, C.S. Lee, and G.P. Pfeifer Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo[a]pyrene diol epoxide in mammalian cells: similarities with the p53 mutation spectrum in smoking-associated lung cancers Cancer Res 61 2001 7110 7117
100. Z. Feng, W. Hu, Y. Hu, and M.S. Tang Acrolein is a major cigarette-related lung cancer agent: preferential binding at p53 mutational hotspots and inhibition of DNA repair Proc Natl Acad Sci U S A 103 2006 15404 15409
101. H. Sasaki, S. Moriyama, and Y. Nakashima Histone deacetylase 1 mRNA expression in lung cancer Lung Cancer 46 2004 171 178
102. M. Nakagawa, Y. Oda, and T. Eguchi Expression profile of class I histone deacetylases in human cancer tissues Oncol Rep 18 2007 769 774
103. B. Bartling, H.S. Hofmann, and T. Boettger Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma Lung Cancer 49 2005 145 154
104. M. Esteller Epigenetics in cancer N Engl J Med 358 2008 1148 1159
105. H. Suzuki, M. Ouchida, and H. Yamamoto Decreased expression of the SIN3A gene, a candidate tumor suppressor located at the prevalent allelic loss region 15q23 in non-small cell lung cancer Lung Cancer 59 2008 24 31
106. A. Van Den Broeck, E. Brambilla, and D. Moro-Sibilot Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer Clin Cancer Res 14 2008 7237 7245
107. J. Hu, Y.L. Liu, S.L. Piao, D.D. Yang, Y.M. Yang, and L. Cai Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer Lung Cancer 77 2012 593 599
108. J. Huang, Y. Qiu, G. Chen, L. Huang, and J. He The relationship between BMI-1 and the epithelial-mesenchymal transition in lung squamous cell carcinoma Med Oncol 29 2012 1606 1613
109. M. Kimura, H. Takenobu, and N. Akita BMI1 regulates cell fate via tumor suppressor WWOX repression in small-cell lung cancer cells Cancer Sci 102 2011 983 990
110. S. Vonlanthen, J. Heighway, and H.J. Altermatt The BMI-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression Br J Cancer 84 2001 1372 1376
111. R.H. Breuer, P.J. Snijders, and E.F. Smit Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis Neoplasia 6 2004 736 743
112. W. Cao, O. Ribeiro Rde, and D. Liu EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer PLoS One 7 2012 e52984
113. M. Takawa, K. Masuda, and M. Kunizaki Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker Cancer Sci 102 2011 1298 1305
114. L. Wan, X. Li, H. Shen, and X. Bai Quantitative analysis of EZH2 expression and its correlations with patients with lung cancer: clinical pathological characteristics Clin Transl Oncol 15 2013 132 138
115. Y. Zhou, C. Wan, and Y. Liu Polycomb group oncogene RING1 is over-expressed in non-small cell lung cancer Pathol Oncol Res 20 2014 549 556
116. T. Sato, A. Kaneda, and S. Tsuji PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer Sci Rep 3 2013 1911
117. Y. Lv, C. Yuan, and X. Xiao The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma Oncol Rep 28 2012 147 154
118. Huqun, R. Ishikawa, and J. Zhang Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer Cancer 118 2012 1599 1606
119. F. Crea, E. Paolicchi, V.E. Marquez, and R. Danesi Polycomb genes and cancer: time for clinical application? Crit Rev Oncol Hematol 83 2012 184 193
120. L.K. Koch, H. Zhou, and J. Ellinger Stem cell marker expression in small cell lung carcinoma and developing lung tissue Hum Pathol 39 2008 1597 1605
121. K. Vrzalikova, J. Skarda, and J. Ehrmann Prognostic value of BMI-1 oncoprotein expression in patients with NSCLC: a tissue microarray study J Cancer Res Clin Oncol 134 2008 1037 1042
122. J.S. Dovey, S.J. Zacharek, C.F. Kim, and J.A. Lees BMI1 is critical for lung tumorigenesis and bronchoalveolar stem cell expansion Proc Natl Acad Sci U S A 105 2008 11857 11862
123. L. Liu, L.G. Andrews, and T.O. Tollefsbol Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death Oncogene 25 2006 4370 4375
124. P. Guan, Z. Yin, X. Li, W. Wu, and B. Zhou Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues J Exp Clin Cancer Res 31 2012 54
125. U. Vosa, T. Vooder, R. Kolde, J. Vilo, A. Metspalu, and T. Annilo Meta-analysis of microRNA expression in lung cancer Int J Cancer 132 2013 2884 2893
126. X. Shi, M. Sun, H. Liu, Y. Yao, and Y. Song Long non-coding RNAs: a new frontier in the study of human diseases Cancer Lett 339 2013 159 166
127. T. Gutschner, M. Hammerle, and S. Diederichs MALAT1: a paradigm for long noncoding RNA function in cancer J Mol Med 91 2013 791 801
128. P. Ji, S. Diederichs, and W. Wang MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer Oncogene 22 2003 8031 8041
129. L.H. Schmidt, T. Spieker, and S. Koschmieder The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth J Thorac Oncol 6 2011 1984 1992
130. T. Gutschner, M. Hammerle, and M. Eissmann The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells Cancer Res 73 2013 1180 1189
131. K. Tano, R. Mizuno, and T. Okada MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes FEBS Lett 584 2010 4575 4580
132. T. Gutschner, M. Baas, and S. Diederichs Noncoding RNA gene silencing through genomic integration of RNA destabilizing elements using zinc finger nucleases Genome Res 21 2011 1944 1954
133. X.H. Liu, Z.L. Liu, M. Sun, J. Liu, Z.X. Wang, and W. De The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer BMC Cancer 13 2013 464
134. T. Nakagawa, H. Endo, and M. Yokoyama Large noncoding RNA HOTAIR enhances aggressive biological behavior and is associated with short disease-free survival in human non-small cell lung cancer Biochem Biophys Res Commun 436 2013 319 324
135. Y. Zhuang, X. Wang, and H.T. Nguyen Induction of long intergenic non-coding RNA HOTAIR in lung cancer cells by type I collagen J Hematol Oncol 6 2013 35
136. A. Lujambio, S. Ropero, and E. Ballestar Genetic unmasking of an epigenetically silenced microRNA in human cancer cells Cancer Res 67 2007 1424 1429
137. Z. Wang, Z. Chen, and Y. Gao DNA hypermethylation of microRNA-34b/c has prognostic value for stage non-small cell lung cancer Cancer Biol Ther 11 2011 490 496
138. E. Nadal, G. Chen, and M. Gallegos Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma Clin Cancer Res 19 2013 6842 6852
139. J. Cao, Y. Song, and N. Bi DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer Cancer Res 73 2013 3326 3335
140. G. Heller, M. Weinzierl, and C. Noll Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers Clin Cancer Res 18 2012 1619 1629
141. B. Brueckner, C. Stresemann, and R. Kuner The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function Cancer Res 67 2007 1419 1423
142. M. Fabbri, R. Garzon, and A. Cimmino MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B Proc Natl Acad Sci U S A 104 2007 15805 15810
143. Q. Feng, S.E. Hawes, and J.E. Stern DNA methylation in tumor and matched normal tissues from non-small cell patients with lung cancer Cancer Epidemiol Biomarkers Prevent 17 2008 645 654
144. S. Toyooka, M. Suzuki, and T. Tsuda Dose effect of smoking on aberrant methylation in non-small cell lung cancers Int J Cancer 110 2004 462 464
145. H. Kim, Y.M. Kwon, and J.S. Kim Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer J Clin Oncol 22 2004 2363 2370
146. Y. Liu, Q. Lan, J.M. Siegfried, J.D. Luketich, and P. Keohavong Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking patients with lung cancer Neoplasia 8 2006 46 51
147. T. Vaissiere, R.J. Hung, and D. Zaridze Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors Cancer Res 69 2009 243 252
148. N. Yanagawa, G. Tamura, H. Oizumi, M. Endoh, M. Sadahiro, and T. Motoyama Inverse correlation between EGFR mutation and FHIT, RASSF1A and RUNX3 methylation in lung adenocarcinoma: relation with smoking status Anticancer Res 31 2011 1211 1214
149. Y.S. Hong, M.S. Roh, and N.Y. Kim Hypermethylation of p16INK4a in Korean non-small cell patients with lung cancer J Korean Med Sci 22 2007 S32 S37
150. P. Andujar, J. Wang, and A. Descatha p16INK4A inactivation mechanisms in non-small-cell patients with lung cancer occupationally exposed to asbestos Lung Cancer 67 2010 23 30
151. F. Liu, J.K. Killian, and M. Yang Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate Oncogene 29 2010 3650 3664
152. J.A. Marwick, P.A. Kirkham, and C.S. Stevenson Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs Am J Respir Cell Mol Biol 31 2004 633 642
153. K. Kaira, N. Sunaga, and Y. Tomizawa Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers Int J Oncol 31 2007 169 173
154. M. Tessema, Y.Y. Yu, and C.A. Stidley Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers Carcinogenesis 30 2009 1132 1138
155. R.K. Lin, Y.S. Hsieh, and P. Lin The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and patients with lung cancer J Clin Invest 120 2010 521 532
156. L.A. Damiani, C.M. Yingling, S. Leng, P.E. Romo, J. Nakamura, and S.A. Belinsky Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells Cancer Res 68 2008 9005 9014
157. J. Wang, Y. Xu, J. Li, X. Sun, L.P. Wang, and W.Y. Ji The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation in laryngeal carcinoma Oral Oncol 48 2012 541 546
158. J. Wang, S.L. Zhao, Y. Li, M. Meng, and C.Y. Qin 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone induces retinoic acid receptor beta hypermethylation through DNA methyltransferase 1 accumulation in esophageal squamous epithelial cells Asian Pacific J Cancer Prevent 13 2012 2207 2212
159. J.A. Hutt, B.R. Vuillemenot, and E.B. Barr Life-span inhalation exposure to mainstream cigarette smoke induces lung cancer in B6C3F1 mice through genetic and epigenetic pathways Carcinogenesis 26 2005 1999 2009
160. L.C. Pulling, B.R. Vuillemenot, J.A. Hutt, T.R. Devereux, and S.A. Belinsky Aberrant promoter hypermethylation of the death-associated protein kinase gene is early and frequent in murine lung tumors induced by cigarette smoke and tobacco carcinogens Cancer Res 64 2004 3844 3848
161. B.R. Vuillemenot, J.A. Hutt, and S.A. Belinsky Gene promoter hypermethylation in mouse lung tumors Mol Cancer Res 4 2006 267 273
162. F. Balkwill, and L.M. Coussens Cancer: an inflammatory link Nature 431 2004 405 406
163. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867
164. X. Meng, and N.H. Riordan Cancer is a functional repair tissue Med Hypotheses 66 2006 486 490
165. H.M. O'Hagan, W. Wang, and S. Sen Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands Cancer Cell 20 2011 606 619
166. C.A. Northrop-Clewes, and D.I. Thurnham Monitoring micronutrients in cigarette smokers Clin Chim Acta 377 2007 14 38
167. M.A. Khaled, and C.L. Krumdieck Association of folate molecules as determined by proton NMR: implications on enzyme binding Biochem Biophys Res Commun 130 1985 1273 1280
168. M. Abu Khaled, C.L. Watkins, and C.L. Krumdieck Inactivation of B12 and folate coenzymes by butyl nitrite as observed by NMR: implications on one-carbon transfer mechanism Biochem Biophys Res Commun 135 1986 201 207
169. R.M. Ortega, A.M. Lopez-Sobaler, and M.M. Gonzalez-Gross Influence of smoking on folate intake and blood folate concentrations in a group of elderly Spanish men J Am Coll Nutr 13 1994 68 72
170. C.J. Piyathilake, M. Macaluso, R.J. Hine, E.W. Richards, and C.L. Krumdieck Local and systemic effects of cigarette smoking on folate and vitamin B-12 Am J Clin Nutr 60 1994 559 566
171. B.C. Blount, M.M. Mack, and C.M. Wehr Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage Proc Natl Acad Sci U S A 94 1997 3290 3295
172. J.Y. Fang, and S.D. Xiao Folic acid, polymorphism of methyl-group metabolism genes, and DNA methylation in relation to GI carcinogenesis J Gastroenterol 38 2003 821 829
173. F.M. Cui, J.X. Li, and Q. Chen Radon-induced alterations in micro-RNA expression profiles in transformed BEAS2B cells J Toxicol Environ Health A 76 2013 107 119
174. S. Su, Y. Jin, and W. Zhang Aberrant promoter methylation of p16(INK4a) and O(6)-methylguanine-DNA methyltransferase genes in workers at a Chinese uranium mine J Occup Health 48 2006 261 266
175. L.C. Pulling, K.K. Divine, and D.M. Klinge Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression Cancer Res 63 2003 4842 4848
176. D.H. Johnson, L. Fehrenbacher, and W.F. Novotny Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191
177. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
178. M. Reck, J. von Pawel, and P. Zatloukal Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil J Clin Oncol 27 2009 1227 1234
179. G. Scagliotti, T. Brodowicz, and F.A. Shepherd Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer J Thorac Oncol 6 2011 64 70
180. Y.J. Kwon, S.J. Lee, and J.S. Koh Genome-wide analysis of DNA methylation and the gene expression change in lung cancer J Thorac Oncol 7 2012 20 33
181. M. Castro, L. Grau, and P. Puerta Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer J Transl Med 8 2010 86
182. S.E. Hawes, J.E. Stern, and Q. Feng DNA hypermethylation of tumors from non-small cell lung cancer (NSCLC) patients is associated with gender and histologic type Lung Cancer 69 2010 172 179
183. W.W. Lockwood, I.M. Wilson, and B.P. Coe Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development PLoS One 7 2012 e37775
184. B.C. Christensen, C.J. Marsit, and E.A. Houseman Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles Cancer Res 69 2009 6315 6321
185. J.A. Bishop, H. Benjamin, H. Cholakh, A. Chajut, D.P. Clark, and W.H. Westra Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach Clin Cancer Res 16 2010 610 619
186. D. Lebanony, H. Benjamin, and S. Gilad Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma J Clin Oncol 27 2009 2030 2037
187. P.C. Hoffman, A.M. Mauer, and E.E. Vokes Lung cancer Lancet 355 2000 479 485
188. J.K. Field, D. Baldwin, and K. Brain CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report Thorax 66 2011 736 737
189. J.M. Isbell, S. Deppen, and J.B. Putnam Jr. Existing general population models inaccurately predict lung cancer risk in patients referred for surgical evaluation Ann Thorac Surg 91 2011 227 233 discussion 233
190. E.O. Machida, M.V. Brock, and C.M. Hooker Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer Cancer Res 66 2006 6210 6218
191. S. Leng, K. Do, and C.M. Yingling Defining a gene promoter methylation signature in sputum for lung cancer risk assessment Clin Cancer Res 18 2012 3387 3395
192. F. de Fraipont, D. Moro-Sibilot, S. Michelland, E. Brambilla, C. Brambilla, and M.C. Favrot Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer? Lung Cancer 50 2005 199 209
193. D. Dietrich, C. Kneip, and O. Raji Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates Int J Oncol 40 2012 825 832
194. V. Schmiemann, A. Bocking, and M. Kazimirek Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study Clin Cancer Res 11 2005 7728 7734
195. Y.C. Hu, D. Sidransky, and S.A. Ahrendt Molecular detection approaches for smoking associated tumors Oncogene 21 2002 7289 7297
196. M. Simkin, M. Abdalla, M. El-Mogy, and Y. Haj-Ahmad Differences in the quantity of DNA found in the urine and saliva of smokers versus nonsmokers: implications for the timing of epigenetic events Epigenomics 4 2012 343 352
197. S.A. Belinsky, K.C. Liechty, and F.D. Gentry Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort Cancer Res 66 2006 3338 3344
198. A.K. Greenberg, B. Rimal, and K. Felner S-adenosylmethionine as a biomarker for the early detection of lung cancer Chest 132 2007 1247 1252
199. J. Shen, N.W. Todd, and H. Zhang Plasma microRNAs as potential biomarkers for non-small-cell lung cancer Lab Invest 91 2011 579 587
200. J. Ma, N. Li, M. Guarnera, and F. Jiang Quantification of plasma miRNAs by digital PCR for cancer diagnosis Biomarker Insight 8 2013 127 136
201. D.G. Weber, G. Johnen, and S. Casjens Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer BMC Res Notes 6 2013 518
202. Y. Shen, T. Wang, and T. Yang Diagnostic value of circulating microRNAs for lung cancer: a meta-analysis Genet Test Mol Biomarkers 17 2013 359 366
203. J. Wang, J.J. Lee, and L. Wang Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer Clin Cancer Res 10 2004 6119 6125
204. J. Gu, D. Berman, and C. Lu Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer Clin Cancer Res 12 2006 7329 7338
205. J.S. Kim, J.W. Kim, J. Han, Y.M. Shim, J. Park, and D.H. Kim Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer Cancer Res 66 2006 4049 4054
206. N. Ota, K. Kawakami, and T. Okuda Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis Anticancer Res 26 2006 3729 3732
207. M. Suzuki, S. Mohamed, and T. Nakajima Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis Int J Oncol 33 2008 113 119
208. T.J. Seng, N. Currey, and W.A. Cooper DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma Br J Cancer 99 2008 375 382
209. H. Usadel, J. Brabender, and K.D. Danenberg Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer Cancer Res 62 2002 371 375
210. M.V. Brock, C.M. Hooker, and E. Ota-Machida DNA methylation markers and early recurrence in stage I lung cancer N Engl J Med 358 2008 1118 1128
211. M. Suzuki, C. Hao, and T. Takahashi Aberrant methylation of SPARC in human lung cancers Br J Cancer 92 2005 942 948
212. M. Yoshino, M. Suzuki, and L. Tian Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers Int J Oncol 35 2009 1201 1209
213. J. Xing, D.J. Stewart, J. Gu, C. Lu, M.R. Spitz, and X. Wu Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer Br J Cancer 98 2008 1716 1722
214. G.M. Strauss, J.E. Herndon 2nd, and M.A. Maddaus Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups J Clin Oncol 26 2008 5043 5051
215. C.R. Kelsey, L.B. Marks, and D. Hollis Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients Cancer 115 2009 5218 5227
216. F. Shoji, A. Haro, and T. Yoshida Prognostic significance of intratumoral blood vessel invasion in pathologic stage IA non-small cell lung cancer Ann Thorac Surg 89 2010 864 869
217. F. Barlesi, G. Giaccone, and M.I. Gallegos-Ruiz Global histone modifications predict prognosis of resected non small-cell lung cancer J Clin Oncol 25 2007 4358 4364
218. D.B. Seligson, S. Horvath, and M.A. McBrian Global levels of histone modifications predict prognosis in different cancers Am J Pathol 174 2009 1619 1628
219. J. Kikuchi, I. Kinoshita, and Y. Shimizu Distinctive expression of the polycomb group proteins BMI1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance Cancer 116 2010 3015 3024
220. X.Y. Zhang, Q.G. Dong, and J.S. Huang The expression of stem cell-related indicators as a prognostic factor in human lung adenocarcinoma J Surg Oncol 102 2010 856 862
221. F. Crea, L. Sun, L. Pikor, P. Frumento, W.L. Lam, and C.D. Helgason Mutational analysis of Polycomb genes in solid tumours identifies PHC3 amplification as a possible cancer-driving genetic alteration Br J Cancer 109 2013 1699 1702
222. M. Yang, H. Shen, and C. Qiu High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer Eur J Cancer 49 2013 604 615
223. Z. Liu, M. Sun, and K. Lu The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregulation of p21(WAF1/CIP1) expression PLoS One 8 2013 e77293
224. E. Zandberga, V. Kozirovskis, A. Abols, D. Andrejeva, G. Purkalne, and A. Line Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer Genes Chromosom Cancer 52 2013 356 369
225. A. Markou, I. Sourvinou, P.A. Vorkas, G.M. Yousef, and E. Lianidou Clinical evaluation of microRNA expression profiling in non small cell lung cancer Lung Cancer 81 2013 388 396
226. C. Sanfiorenzo, M.I. Ilie, and A. Belaid Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC PLoS One 8 2013 e54596
227. M. Boeri, C. Verri, and D. Conte MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer Proc Natl Acad Sci U S A 108 2011 3713 3718
228. Z. Hu, X. Chen, and Y. Zhao Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer J Clin Oncol 28 2010 1721 1726
229. X.G. Liu, W.Y. Zhu, and Y.Y. Huang High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer Med Oncol 29 2012 618 626
230. J. Silva, V. Garcia, and A. Zaballos Vesicle-related microRNAs in plasma of nonsmall cell patients with lung cancer and correlation with survival Eur Respir J 37 2011 617 623
231. Z.X. Wang, H.B. Bian, J.R. Wang, Z.X. Cheng, K.M. Wang, and W. De Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer J Surg Oncol 104 2011 847 851
232. J. Wei, W. Gao, and C.J. Zhu Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer Chinese J Cancer 30 2011 407 414
233. E.A. Houseman, W.P. Accomando, and D.C. Koestler DNA methylation arrays as surrogate measures of cell mixture distribution BMC Bioinformatics 13 2012 86
234. J.L. Ramirez, R. Rosell, and M. Taron 14-3-3sigma Methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell patients with lung cancer predicts survival: the Spanish Lung Cancer Group J Clin Oncol 23 2005 9105 9112
235. A.A. Ponomaryova, E.Y. Rykova, and N.V. Cherdyntseva RARbeta2 gene methylation level in the circulating DNA from blood of patients with lung cancer Eur J Cancer Prevent 20 2011 453 455
236. B. Li, S. Ren, and X. Li miR-21 Overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer Lung Cancer 83 2014 146 153
237. Y.S. Wang, Y.H. Wang, H.P. Xia, S.W. Zhou, G. Schmid-Bindert, and C.C. Zhou MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines Asian Pacific J Cancer Prevent 13 2012 255 260
238. M. Garofalo, G. Romano, and G. Di Leva EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers Nat Med 18 2012 74 82
239. M. Zhong, X. Ma, C. Sun, and L. Chen MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer Chem Biol Interact 184 2010 431 438
240. K. Kitamura, M. Seike, and T. Okano miR-134/487b/655 Cluster regulates TGF-beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells Mol Cancer Ther 13 2014 444 453
241. M. Cao, M. Seike, and C. Soeno miR-23a Regulates TGF-beta-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells Int J Oncol 41 2012 869 875
242. S. Cufi, R. Bonavia, and A. Vazquez-Martin Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo Sci Rep 3 2013 2459
243. J.L. Bryant, J. Britson, and J.M. Balko A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT Br J Cancer 106 2012 148 156
244. M. Zhan, Q. Qu, G. Wang, and H. Zhou let-7c Sensitizes acquired cisplatin-resistant A549 cells by targeting ABCC2 and Bcl-XL Pharmazie 68 2013 955 961
245. Z. Dong, Z. Zhong, L. Yang, S. Wang, and Z. Gong MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9 Cancer Lett 343 2014 249 257
246. Y. Li, L. Li, Y. Guan, X. Liu, Q. Meng, and Q. Guo miR-92b Regulates the cell growth, cisplatin chemosensitivity of A549 non small cell lung cancer cell line and target PTEN Biochem Biophys Res Commun 440 2013 604 610
247. L. Song, Y. Li, W. Li, S. Wu, and Z. Li miR-495 Enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A) J Cell Biochem 115 2014 1234 1242
248. T. Qiu, L. Zhou, and T. Wang miR-503 Regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2 Int J Mol Med 32 2013 593 598
249. Q. Xiang, H. Tang, J. Yu, J. Yin, X. Yang, and X. Lei MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2 Pharmazie 68 2013 274 281
250. L. Zhou, T. Qiu, and J. Xu miR-135a/b Modulate cisplatin resistance of human lung cancer cell line by targeting MCL1 Pathol Oncol Res 19 2013 677 683
251. L.M. Pouliot, D.W. Shen, T. Suzuki, M.D. Hall, and M.M. Gottesman Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells Exp Cell Res 319 2013 566 574
252. Y.S. Zang, Y.F. Zhong, Z. Fang, B. Li, and J. An miR-155 Inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of APAF-1 expression Cancer Gene Ther 19 2012 773 778
253. Z.L. Liu, H. Wang, J. Liu, and Z.X. Wang MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN Mol Cell Biochem 372 2013 35 45
254. W. Zhu, H. Xu, and D. Zhu miR-200bc/429 Cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP Cancer Chemother Pharmacol 69 2012 723 731
255. P. Ceppi, G. Mudduluru, and R. Kumarswamy Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer Mol Cancer Res 8 2010 1207 1216
256. Q. Wang, M. Zhong, W. Liu, J. Li, J. Huang, and L. Zheng Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP) Exp Lung Res 37 2011 427 434
257. H.B. Bian, X. Pan, J.S. Yang, Z.X. Wang, and W. De Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549) J Exp Clin Cancer Res 30 2011 20
258. W. Zhu, D. Zhu, and S. Lu miR-497 Modulates multidrug resistance of human cancer cell lines by targeting BCL2 Med Oncol 29 2012 384 391
259. W. Zhu, X. Shan, T. Wang, Y. Shu, and P. Liu miR-181b Modulates multidrug resistance by targeting BCL2 in human cancer cell lines Int J Cancer 127 2010 2520 2529
260. X.C. Wang, W. Wang, Z.B. Zhang, J. Zhao, X.G. Tan, and J.C. Luo Overexpression of miRNA-21 promotes radiation-resistance of non-small cell lung cancer Radiat Oncol 8 2013 146
261. S. Grosso, J. Doyen, and S.K. Parks miR-210 Promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines Cell Death Dis 4 2013 e544
262. H. Salim, N.S. Akbar, and D. Zong miRNA-214 Modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence Br J Cancer 107 2012 1361 1373
263. K.M. Lee, E.J. Choi, and I.A. Kim MicroRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling Radiother Oncol 101 2011 171 176
264. H. Arora, R. Qureshi, S. Jin, A.K. Park, and W.Y. Park miR-9 And let-7g enhance the sensitivity to ionizing radiation by suppression of NFkappaB1 Exp Mol Med 43 2011 298 304
265. S.H. Jeong, H.G. Wu, and W.Y. Park LIN28B confers radio-resistance through the posttranscriptional control of KRAS Exp Mol Med 41 2009 912 918
266. S.V. Sharma, D.Y. Lee, and B. Li A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Cell 141 2010 69 80
267. M. Gerlinger, A.J. Rowan, and S. Horswell Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 2012 883 892
268. M. Kodani, T. Igishi, and S. Matsumoto Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells Oncol Rep 13 2005 477 483
269. X.D. Yu, S.Y. Wang, and G.A. Chen Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells Cancer J 13 2007 105 113
270. Y.H. Choi Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells Int J Oncol 27 2005 473 479
271. S. Doi, H. Soda, and M. Oka The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells Mol Cancer Ther 3 2004 1397 1402
272. M. Tong, Y. Ding, and H.H. Tai Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells Biochem Pharmacol 72 2006 701 709
273. V.O. Kaminskyy, O.V. Surova, A. Vaculova, and B. Zhivotovsky Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL Carcinogenesis 32 2011 1450 1458
274. J.S. Nam, Y. Ino, Y. Kanai, M. Sakamoto, and S. Hirohashi 5-Aza-2′-deoxycytidine restores the E-cadherin system in E-cadherin-silenced cancer cells and reduces cancer metastasis Clin Exp Metastasis 21 2004 49 56
275. W.W. Lockwood, K. Zejnullahu, J.E. Bradner, and H. Varmus Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins Proc Natl Acad Sci U S A 109 2012 19408 19413
276. M. Rao, N. Chinnasamy, and J.A. Hong Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer Cancer Res 71 2011 4192 4204
277. M.W. Lawless, K.J. O'Byrne, and S.G. Gray Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy J Cell Mol Med 13 2009 2800 2821
278. S. Rangwala, C. Zhang, and M. Duvic HDAC inhibitors for the treatment of cutaneous T-cell lymphomas Future Med Chem 4 2012 471 486
279. R.A. Juergens, J. Wrangle, and F.P. Vendetti Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer Cancer Discovery 1 2011 598 607